Grifols (GRFS) Q2 2025 Earnings Call July 29, 2025 12:30 PM ET Speaker0Hello, everyone. My name is Dani Segarra, and I serve as a Head of Investor Relations and Sustainability and Vice President at Grifols. Welcome to our review of the company's business results for the 2025. Today, I'm joined by Grifols' Chief Executive Officer, Nat Chavia Chief Financial Officer, Rahul Isrinivasan and the President of BioPharma, Roland Vandeler. A few logistics before we get into the details.Today's call will last about a ...

Q2 2025 Results July 29, 2025 Q2 2025 Results - 2 - Q2 2025 Results - 1 - Legal Disclaimer Important Information This presentation does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, the Spanish Securi ...

Core Insights - XL-protein GmbH has entered into a worldwide License, Development and Commercialization Agreement with Grifols for a novel long-acting biopharmaceutical product [1] - The collaboration will utilize XL-protein's PASylation® technology to enhance the circulation and effectiveness of Grifols' therapeutics [2] - Financial terms include an upfront payment, milestone payments, and tiered royalties on sales from marketed therapeutics, with Grifols holding exclusive marketing rights [3] Company Overview - Grifols is a global healthcare company founded in 1909, specializing in plasma-derived medicines and innovative healthcare solutions across more than 110 countries [6] - XL-protein is a privately owned biotech company based in Germany, focusing on developing biologics with extended half-life and enhanced in vivo activity through its PASylation® technology [6]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell even higher, with the expectation that established trends will continue [1][2]. Company Overview: Grifols (GRFS) - Grifols currently holds a Momentum Style Score of A, indicating strong momentum potential [3]. - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for outperformance in the market [4]. Performance Metrics - Over the past week, Grifols shares increased by 2.47%, while the Zacks Medical - Drugs industry remained flat [6]. - In a longer timeframe, Grifols' shares have risen by 15.44% over the past month, significantly outperforming the industry's 3.53% [6]. - For the past quarter, Grifols shares increased by 8.89%, and over the last year, they gained 15.12%, compared to the S&P 500's 3.59% and 14.21% respectively [7]. Trading Volume - Grifols has an average 20-day trading volume of 819,084 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - In the last two months, one earnings estimate for Grifols has increased, while none have decreased, raising the consensus estimate from $0.96 to $0.99 [10]. - For the next fiscal year, one estimate has also moved upwards with no downward revisions [10]. Conclusion - Given the strong performance metrics and positive earnings outlook, Grifols is recommended as a solid momentum pick for investors [11][12].

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and ...

Core Viewpoint - Investors in the Medical - Drugs sector should consider Grifols (GRFS) and Stevanato Group (STVN) for potential value opportunities [1] Group 1: Zacks Rank and Earnings Outlook - Grifols has a Zacks Rank of 2 (Buy), indicating a stronger earnings outlook compared to Stevanato Group, which has a Zacks Rank of 3 (Hold) [3] - The Zacks Rank strategy focuses on companies with positive earnings estimate revision trends, which is a key consideration for value investors [2] Group 2: Valuation Metrics - Grifols has a forward P/E ratio of 8.39, significantly lower than Stevanato Group's forward P/E of 39.52, suggesting that GRFS may be undervalued [5] - The PEG ratio for Grifols is 0.29, indicating a favorable valuation relative to its expected earnings growth, while Stevanato Group has a PEG ratio of 2.13 [5] - Grifols also has a P/B ratio of 0.65, compared to Stevanato Group's P/B of 4.51, further highlighting the relative undervaluation of GRFS [6] Group 3: Overall Value Assessment - Grifols earns a Value grade of A, while Stevanato Group receives a Value grade of C, indicating that GRFS is viewed more favorably by value investors [6] - The combination of Zacks Rank and Style Scores suggests that Grifols is the better investment option at this time [6]

Core Viewpoint - ADMA Biologics and Grifols are prominent players in the plasma-derived therapies market, each with unique strengths and growth prospects, making stock selection challenging [1][2]. Company Overview ADMA Biologics - ADMA specializes in plasma-derived biologics for treating immune deficiencies and preventing infectious diseases, with three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [3][6]. - Asceniv, the lead product, is a plasma-derived IVIG that contains polyclonal antibodies to neutralize microbes [4][5]. - The company anticipates significant revenue growth from Asceniv, driven by record demand and plans for a new R&D program, SG-001, which could generate $300-500 million in annual revenues [6]. Grifols - Grifols is a global leader in plasma-derived medicines, developing a wide range of biological therapies targeting various immunological conditions [7][8]. - The company reported sales of €7.2 billion in 2024, reflecting a 10.3% increase, and is recognized as the largest producer of A1PI [9][10]. - Grifols has a diverse portfolio and is positioned for consistent growth due to strong demand and operational execution [11]. Financial Estimates ADMA Biologics - The Zacks Consensus Estimate for ADMA's 2025 sales indicates an 18.61% year-over-year increase, with EPS expected to improve by 36.73% [12]. - Recent estimate revisions show a decline in EPS estimates for 2025 but an increase for 2026 [13]. Grifols - The Zacks Consensus Estimate for Grifols' 2025 sales suggests a 3.78% increase, with EPS expected to rise by 296% [12]. - EPS estimates for both 2025 and 2026 have seen upward revisions in the past 60 days [15]. Price Performance and Valuation - Year-to-date, ADMA shares have increased by 15.9%, outperforming Grifols' 10.6% rise, while the industry has declined by 4.1% [16]. - In terms of valuation, ADMA trades at 25.48X forward earnings, significantly higher than Grifols' 7.19X [16]. Investment Recommendation - ADMA shows steady growth driven by Asceniv demand, while Grifols, with a broader portfolio and better valuation, is considered a more favorable investment choice at present [20][21][22].

Group 1 - The article discusses the author's long position in the shares of GRFS and UNM, indicating a positive outlook on these companies [1] - It emphasizes the importance of conducting due diligence and research before making any investment decisions, particularly for short-term trading and options trading [2] - The article clarifies that past performance is not indicative of future results, and no specific investment recommendations are provided [3]

Core Viewpoint - Grifols (GRFS) is currently positioned as a better value opportunity compared to Neurocrine Biosciences (NBIX) based on various valuation metrics and earnings outlook [1][3]. Valuation Metrics - GRFS has a forward P/E ratio of 7.65, significantly lower than NBIX's forward P/E of 31.35, indicating that GRFS may be undervalued [5]. - The PEG ratio for GRFS is 0.26, while NBIX's PEG ratio is 1.22, suggesting that GRFS has a more favorable earnings growth outlook relative to its price [5]. - GRFS's P/B ratio stands at 0.60, compared to NBIX's P/B of 4.63, further highlighting GRFS's relative undervaluation [6]. Earnings Outlook - GRFS has a Zacks Rank of 2 (Buy), indicating a stronger improvement in its earnings outlook compared to NBIX, which has a Zacks Rank of 3 (Hold) [3][6]. - The overall valuation metrics and solid earnings outlook position GRFS as the superior value option in the current market [6].

Company Overview - Grifols conducted a conference call to review its Business Results for the First Quarter of 2025, featuring key executives including the CEO, CFO, and President of Biopharma [1]. Logistics and Presentation - The conference call is expected to last about an hour, including a Q&A session, and is being recorded for future reference [2]. - Additional materials, including the presentation, are available on the Grifols Investor Relations website [2]. Financial Reporting - All financial statements are prepared in accordance with EU IFRS and other applicable reporting provisions, including alternative performance measures (APMs) [4]. - Grifols management utilizes APMs to assess financial performance, cash flow, and overall business health [4].